CXCL13 antagonists and their use for the treatment of inflammatory diseases
AssigneeCentocor, Inc.
InventorsPeter Bugelski, Anuk Das, Donald E. Griswold, Bailin Liang, Li Li, Robert T. Sarisky, Xiaozhou Shang
Life of this patent
Estimating the term…
Loading patent…
AssigneeCentocor, Inc.
InventorsPeter Bugelski, Anuk Das, Donald E. Griswold, Bailin Liang, Li Li, Robert T. Sarisky, Xiaozhou Shang
Estimating the term…
Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFα antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
A method for treating a CXCL13 activity-related disorder in a cell, tissue, organ or animal comprising:
A method for treating an animal with systemic lupus erythematosus comprising:
Dependencies are inferred from the claim text.